NYMXFOTC

NYMOX PHARMACEUTICAL CORP

Healthcare·Oncology·Commercial·Nassau, Bahamas
OncologyRare DiseaseNeurologyImmunologyOphthalmologyCardiovascularInfectious DiseaseMetabolicRespiratoryDermatologyPsychiatry

NYMOX PHARMACEUTICAL CORP (NYMXF): 77 pipeline candidates · 7 upcoming catalysts · 34 clinical trials. Updated within the last hour.

10.0/10

BioSniper Score

4-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health10.0

D/E -1.10 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth10.0

77 candidates

Catalyst Momentum10.0

7 upcoming, next in ~133d

Insider SignalN/A

N/A

A transparent, data-derived signal for NYMOX PHARMACEUTICAL CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$13.0M

Cash

—

Quarterly Burn

—

Runway

—

Revenue

—

Cash Runway vs Catalysts

Upcoming catalyst timeline.

Today~21 mo out
Catalyst within runway

Pipeline (77 candidates)

DrugPhase
amphotericin b liposome for injection (strength—
amphotericin b liposome for injection (trade name—
apixabanApproved
avp-786Phase 3
bedaquilinePhase 2/Phase 3
bl-m24d1Phase 1
carbon nanoparticle ironPhase 2
carbon nanoparticle ironPhase 2
ceftazidime-avibactamPhase 3
centanafadinePhase 3

Showing 10 of 77 candidates. Sign up for full pipeline.

Upcoming Catalysts (7)

Phase3_ToplinePhase 3 Topline: A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Trial to Evalua

Clinical data readout — efficacy/safety results are a high-impact catalyst.

68.6% historical Phase 3 primary-endpoint success rate (n=363)

Phase3_ToplinePhase 3 Topline: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Trial on the Effic

Clinical data readout — efficacy/safety results are a high-impact catalyst.

68.6% historical Phase 3 primary-endpoint success rate (n=363)

Patent_ExpiryPatent/Exclusivity Expiry: SIRTURO

Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.

Phase3_ToplinePhase 3 Topline: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy an

Clinical data readout — efficacy/safety results are a high-impact catalyst.

68.6% historical Phase 3 primary-endpoint success rate (n=363)

Phase3_ToplinePhase 3 Topline: A Phase Ⅲ Randomized, Parallel-group, Placebo-controlled Trial to Assess the Efficacy, Safety of the

Clinical data readout — efficacy/safety results are a high-impact catalyst.

68.6% historical Phase 3 primary-endpoint success rate (n=363)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

1

Total value held

$2K

HolderSharesValue
first citizens financial corp35,100$2K
34 clinical trials·1 FDA decision·CEO: Dr. Paul Averback DABP, M.D.

Frequently asked questions

How many drug candidates are in NYMOX PHARMACEUTICAL CORP's pipeline?

NYMOX PHARMACEUTICAL CORP (NYMXF) has 77 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is NYMOX PHARMACEUTICAL CORP's next catalyst?

NYMOX PHARMACEUTICAL CORP's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Trial to Evalua" — expected October 29, 2026.

What is NYMOX PHARMACEUTICAL CORP's market capitalization?

NYMOX PHARMACEUTICAL CORP's market capitalization is approximately $13.0M.

Who is the CEO of NYMOX PHARMACEUTICAL CORP?

Dr. Paul Averback DABP, M.D. is the chief executive officer of NYMOX PHARMACEUTICAL CORP (NYMXF).

Get the full picture on NYMOX PHARMACEUTICAL CORP

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar